Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Daiichi Sankyo Co., Ltd.

https://www.daiichisankyo.com/index.html

Latest From Daiichi Sankyo Co., Ltd.

Merck As Anchor, Scale As Lever, Aurobindo Looks To Spar With Lonza, WuXi Group

Bookmark
  • Analysis
By Vibha Ravi

Starting off with MSD as an anchor partner, Aurobindo plans to eventually spar with the likes of WuXi and Lonza while building scale for its biologics CDMO business. Meanwhile, EMA approval for a greenfield project in China and an US FDA nod for Ryzneuta, licensed from Yifan’s Evive Biotech, signal a boost.

Strategy Sales & Earnings

Japan’s CEA Scheme: How It Works And Impact So Far

Bookmark
  • Analysis
By Lisa Takagi

Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?

Japan Reimbursement

Merck As Anchor, Scale As Lever, Aurobindo Looks To Spar With Lonza, WuXi Group

Bookmark
  • Analysis
By Vibha Ravi

Starting off with MSD as an anchor partner, Aurobindo plans to eventually spar with the likes of WuXi and Lonza while building scale for its biologics CDMO business. Meanwhile, EMA approval for a greenfield project in China and an US FDA nod for Ryzneuta, licensed from Yifan’s Evive Biotech, signal a boost

Business Strategies Commercial

Are Korean Biopharma Alliances Recovering After Gloomy Year?

Bookmark
  • Analysis
By Jung Won Shin

Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.

South Korea Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Ambit Biosciences Corporation
    • Asubio Pharmaceuticals, Inc.
    • Daiichi Sankyo RD Novare Co., Ltd.
    • Kitasato Daiichi Sankyo K.K.
    • Im Co., Ltd., Luitpold Pharmaceuticals, Inc. (American Regent, Inc., PharmaForce, Inc.)
    • Plexxikon Inc.
    • Ranbaxy Laboratories Ltd.
    • Roxro Pharma, Inc.
    • Sankyo Pharma
    • Suntory Pharmaceutical
    • U3 Pharma AG
    • Daiichi Sankyo India Pharma Private Limited
    • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
    • Zenotech Laboratories Ltd.
    • Daiichi Sankyo Vietnam Company Limited.
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By